Loading...
XKRX
005690
Market cap444mUSD
Jul 10, Last price  
12,030.00KRW
1D
7.89%
1Q
-28.14%
Jan 2017
131.79%
Name

Pharmicell Co Ltd

Chart & Performance

D1W1MN
XKRX:005690 chart
P/E
17.90
P/S
6.33
EPS
672.11
Div Yield, %
—
Shrs. gr., 5y
0.02%
Rev. gr., 5y
24.75%
Revenues
114.06b
+75.88%
12,262,427,0008,327,605,0007,188,425,0006,368,840,00010,282,423,52011,111,800,24033,405,394,27020,155,408,36025,176,279,99027,839,155,88025,197,458,94028,351,801,13032,481,967,12037,752,048,00051,811,621,00060,181,807,00056,227,379,00064,851,304,000114,061,538,000
Net income
40.33b
+536.99%
-907,860,000-4,432,368,000-3,953,213,000-13,832,579,000-18,172,653,000-17,642,754,530-25,700,634,600-28,768,437,020-6,390,211,570-676,712,100-39,196,611,390-12,680,884,1704,347,128,2805,241,801,0009,450,907,0008,261,769,0003,577,984,0006,331,277,00040,329,514,000
CFO
41.05b
+1,073.58%
-745,665,0002,383,405,000-5,141,365,000-5,550,394,000-16,166,405,990-11,868,349,760-2,687,726,820-8,772,026,860-2,411,175,620988,968,270-2,007,324,1003,404,989,340-75,498,8808,978,054,530-5,222,200,0007,914,448,00011,814,412,0003,498,233,00041,054,698,000
Dividend
Dec 27, 202420 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Headquartered in Seoul, South Korea, Pharmicell Co., Ltd. is a biopharmaceutical company established in 2002, actively developing and marketing stem cell treatments across South Korea and globally. The firm operates through two primary segments: Biopharmaceutical Business and Biochemical Business. Its flagship approved product, Cellgram_AMI, leverages a patient's own bone marrow-derived mesenchymal stem cells to enhance heart pumping capacity (ejection fraction) in individuals who have suffered acute myocardial infarction and subsequently undergone coronary angioplasty. Beyond this, Pharmicell is actively progressing several pipeline candidates, including Cellgram_LC for liver ailments, Cellgram_ED targeting impotence, Cellgram_DC for cancer treatment, and Hearticellgram_AM for various cardiac conditions. In its Biochemical division, the company produces crucial intermediates for pharmaceutical raw materials, such as nucleosides, mPEGs, and HDP-tosylate, alongside manufacturing specialized industrial materials like low dielectric constant substances and eco-friendly flame retardants. Furthermore, Pharmicell operates "Twelve," a dedicated stem cell bank, and formulates cosmetics utilizing stem cell culture media.
URL
http://www.pharmicell.com/
IPO date
May 20, 1988
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT